Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Exclusive Story from MarketBeat.com
Abbott Stock Crash: Rebound Could Be Coming FastBy Thomas Hughes. Originally Published: 4/17/2026. 
Key Points
- Abbott Laboratories' stock price sell-off is overblown and unrealistic, providing an attractive opportunity in Q2.
- Institutions and analysts are accumulating this stock, indicating solid double-digit upside potential.
- Acquisitional woe hinders price action in April, but sets the market up for positive surprises and rebound later this year.
- Special Report: Elon Musk’s $1 Quadrillion AI IPO
Abbott Laboratories' (NYSE: ABT) share price corrected by approximately 45% from peak to trough, bottoming in early Q2 2026 after reaching incredibly oversold levels.
For a moment…
Forget about Trump’s ties to Israel.
Forget about reports of Iran’s nuclear program.
Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. Click here to find out what it is.
There are reasons for the sell-off, but the magnitude looks excessive given the underlying factors. Mixed results at the end of 2025 were compounded by cautious guidance and concerns around an acquisition, which left the market disappointed. The question is who is doing the selling and who isn’t — and the data aren’t all that surprising. ABT Stock Is Well-Supported by Sell-Side InterestsMarketBeat’s data shows continued sell-side support for Abbott. Of the 21 tracked analysts, the consensus remains a Moderate Buy, with an 81% Buy-side bias and a steady price-target trend. Some price-target cuts followed the Q4 results, but those adjustments were largely in line with consensus and sentiment has become more constructive since. Barclays analyst Matt Miksic boosted his target in early April, affirming an Overweight rating and setting a $144 target — roughly 7.5% above consensus and about 40% above key support levels. Institutions are also bullish, owning more than 75% of the float and having accumulated for seven consecutive months. Early Q2 activity shows some distribution, but that can reverse quickly. In Q1 2026 bullish activity ramped, reaching multiyear highs even as the stock declined. If institutional buyers take advantage of the post-earnings weakness, Abbott’s downside floor is likely in the mid-$90s. Abbott Laboratories Market Hits Bottom in Q2The ABT stock price pulled back sharply after the Q1 release and could move lower, but early action suggests a bottoming process. The market gapped down at the open and then traded in a tight range near critical support levels, showing steady trading at these lows. Volume spiked alongside the price dip, reaching long-term intraday highs — a pattern consistent with accumulation. 
Technical indicators point to a potential rebound. The stochastic oscillator shows deeply oversold levels while the MACD divergence suggests bears are losing control and bulls are taking over. A clear catalyst could accelerate the recovery — for example, visible progress integrating Exact Sciences, the maker of Cologuard and Abbott’s entry into the higher-growth oncology diagnostics market. The main risk is that the stock languishes near current lows for several quarters, but even that scenario presents buying opportunities. Investors can target support levels as entry points and add to positions over time. Abbott Laboratories Falls Despite a Strong QuarterAbbott didn’t report a bad quarter, though management confirmed a near-term impact from the acquisition. Revenue rose 7.8% year over year, with comparable (organic) growth of 3.7%. Foreign exchange added roughly 400 basis points, with U.S. sales up 2.5% and international sales increasing about 4.5%. By segment, Nutrition was the weakest, down 7.7% due to volume and pricing headwinds, while other segments grew. Diagnostics rose 2.5% but should pick up now that Exact Sciences is in the portfolio. Established Pharmaceuticals and Medical Technology led the company, up 9% and 8.1%, respectively, underscoring the benefits of diversification. Margins disappointed relative to the top line, but that alone does not justify a near-50% sell-off. Adjusted earnings were in line with expectations despite 145 basis points of top-line strength. The bottom line is that results support the company’s strong balance sheet and ongoing capital-return program, and guidance remains constructive. Management Guides In Line With ExpectationsLooking ahead, management expects sequential revenue acceleration and margin recovery, forecasting 7% comparable growth at the midpoint and $5.48 in annual adjusted EPS — a penny above consensus. Given Abbott’s track record of successful acquisitions and integrations, execution could produce upside to those targets. In the meantime, Abbott’s dividend and share buybacks are likely to continue. The dividend yields a historically high 2.5% at mid-April prices and comes with a strong pedigree: ABT is both a Dividend Aristocrat and a Dividend King, having raised its distribution for more than 50 consecutive years. |
0 Response to "We're excited to have you on board"
Post a Comment